Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110577 | 0.84 | KDM4E (0.33) | L3MBTL1HTTKDM4EALDH1A1 | |
| SCHEMBL17164275 | 0.82 | LTA4H (0.35) | L3MBTL1CYP1A2CYP2D6CYP2C19TSHR | |
| SCHEMBL17164318 | 0.79 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL17110583 | 0.75 | L3MBTL1 (0.32) | NQO1L3MBTL1TUBB1KDM1A | |
| SCHEMBL15939840 | 0.75 | POLB (0.33) | — | |
| SCHEMBL15067514 | 0.75 | SYK (0.33) | — | |
| SCHEMBL15067388 | 0.75 | HTR2C (0.39) | L3MBTL1TSHR | |
| SCHEMBL4447973 | 0.74 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL17164140 | 0.73 | PARP10 (0.36) | — | |
| SCHEMBL17110614 | 0.73 | FFAR4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129358-A1 | DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES | BASF SE (DE) | 2017-02-15 | — | — | EP | claimed |
| US-20170029383-A1 | Diaminotriazine Derivatives as Herbicides | BASF SE (DE) | 2017-02-02 | — | — | US | claimed |
| WO-2015155271-A1 | DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES | BASF SE (DE) | 2015-10-15 | — | — | WO | claimed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-20170101383-A1 | DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES | BASF SE (DE) | 2017-04-13 | — | — | US | disclosed |
| EP-3129358-A1 | DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES | BASF SE (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029383-A1 | Diaminotriazine Derivatives as Herbicides | BASF SE (DE) | 2017-02-02 | — | — | US | disclosed |
| EP-3122736-A1 | DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES | BASF SE (DE) | 2017-02-01 | — | — | EP | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| WO-2015144881-A1 | DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES | BASF SE (DE) | 2015-10-01 | — | — | WO | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-9040709-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-25 | — | — | US | disclosed |
| US-8884010-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | NQO1 1074/4885L3MBTL1 4737/4885HTT 2161/4885 |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | NQO1 3/4885L3MBTL1 2609/4885HTT 2016/4885 |
| US-20170101383-A1 | DIAMINOTRIAZINE DERIVATIVES AS HERBICIDES | DRD3, CBR3, ATL3 | NQO1 1820/4885L3MBTL1 1218/4885HTT 2840/4885 |
| US-20170029383-A1 | Diaminotriazine Derivatives as Herbicides | DDT, CBR3, HDHD5 | NQO1 303/4885L3MBTL1 1146/4885HTT 439/4885 |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | NQO1 3/4885L3MBTL1 2609/4885HTT 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.